JBIO

Jade Biosciences, Inc.

BS score 54.8MEDIUMPHASE1 · mkt cap $899.0M · rev ttm $0

drug hypothesis

JADE101 modulates Not disclosed to treat Not specified; Phase 1 study in healthy volunteers suggests first-in-human dose escalation for undetermined therapeutic area.

moa:Not disclosed in available filing materials

score breakdown

trial design20

base rate disconnect67

language red flags100

composite54.8

valuation analysis

market cap$899.0M

revenue ttm$0

phasePHASE1

historical base rate8%

disconnect ratio2.2x

lead trialNCT07059312

meta

cik0001798749

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study in 32 healthy participants

primary endpoint:Safety and Tolerability of Single Ascending Doses of JADE101 in Healthy Participants (Day 1 through 48 weeks)

claimed differentiation

Not disclosed

language red flags

Filing content appears incomplete (only '1' visible in business section)
No target or mechanism of action disclosed
No indication specified despite Phase 1 trial underway
No preclinical data provided
No stated differentiation or competitive positioning
Generic placeholder content suggests material may be missing or redacted

company-stated risks

No risks explicitly stated in available filing

upcoming catalysts

2026-10Primary completion